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ORIGINAL RESEARCH    
Gold nanoparticle charge modulates T cell proliferation 
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To address how surface charge affects the fate of potential nanocarriers in the lung, gold 
nanoparticles (AuNPs) coated with polyvinyl alcohol containing either positively (NH2) or negatively 
(COOH) charged functional groups were intra-nasally instilled in mice, and their uptake by antigen 
presenting cell populations (APC) in broncho-alveolar lavage (BAL) fluid, trachea, and lung 
parenchyma, as well as trafficking to the lung draining lymph nodes (LDLNs) was assessed by flow 
cytometry. Furthermore, CD4+ T cell proliferation in LDLNs was investigated following instillation. All 
APC subpopulations preferentially captured positively-charged AuNPs compared to their negatively-
charged counterparts. Uptake of AuNPs up-regulated expression of co-stimulatory molecules on all 
APC populations. Furthermore, positively-charged AuNPs induced enhanced OVA-specific CD4+ T cell 
stimulation in LDLNs compared to negatively-charged AuNPs, or polymer alone. Our findings 
demonstrate surface charge as a key parameter determining particle uptake by APC, and down-
























The lung is an ideal target organ for needle-free immune modulatory or vaccination approaches 
given its large surface area endowed by a dense network of antigen-presenting cell populations such 
as dendritic cells (DCs) and macrophages. Drug delivery through the pulmonary route offers several 
additional advantages over oral or parenteral delivery due to the presence of a dense vasculature, 
and a lower concentration of drug-metabolizing enzymes in the lung combined with the highly 
dispersed nature of an aerosol.1 Free antigen delivered to the respiratory tract, however, usually fails 
to induce robust protective effects due to rapid degradation.2 For these reasons, in recent years, 
engineered nanomaterials have gained increased interest in the field of innovative biomedical 
applications. In particular, engineered nanoparticle (NP)-based carrier systems (e.g. mainly NPs with 
all three dimensions below 100nm (ISO/TS, 2008)) have been proposed as novel therapeutic 
applications to deliver encapsulated or conjugated molecules of interest (e.g. antigens, allergens, 
drugs, peptides, proteins, genes, etc.) directly to specific cellular targets, such as antigen-presenting 
cells (APCs), or more specifically DCs.3–5 Depending on the degradation rate of the NP-based carrier, 
such an approach would enable controlled antigen release over time for novel immune-modulatory 
strategies.6 To date an increasing number of studies regarding inhalable NP-based carriers is 
emerging emphasizing the importance of respiratory tract targeting biomedical approaches. For 
example, recent studies with mice using in particular bio-mimetic nanoparticles demonstrated 
prolonged persistence, lower inflammatory potential, increased antigen transport to draining lymph 
nodes, improved specific effector memory T cell responses and significant protection against 
respiratory challenge infection.789 In addition, several aerosolized vaccines, such as NP-conjugated to 
ovalbumin, are being developed and have shown promising first results.10,11 12  
 
We and others have shown in the past that NPs not only can serve as carriers, but are also endowed 
with intrinsic immuno-modulatory properties that may either be required or undesirable for a 


















functionalization with different coatings and charges may alter interactions of NPs with immune 
cells. For instance, we recently reported that intra-nasally administered polystyrene particles with a 
diameter of 20 nm were more frequently captured by DCs, compared to larger 1000 nm particles, 
and only the smallest particles led to enhanced antigen-specific CD4+ T cell proliferation in lung 
draining lymph nodes (LDLNs).13 Despite an increasing body of literature in the area, little is known 
on how NP surface chemistry and charge govern interaction with resident APC populations in 
different respiratory tract compartments upon inhalation. 
 
We hypothesized that NP functionalization with different surface charges, i.e. either positive or 
negative, on gold core-bound polymer will influence uptake, trafficking to DLNs and induction of 
down-stream immune responses by respiratory tract APC populations. We utilized gold NPs (AuNPs) 
coated with functionalized positively-charged (NH3
+) or negatively-charged (COO-) polyvinyl alcohol 
(PVA) polymers, as it was shown that such polymers improve the colloidal stability and 
biocompatibility of NPs.16 We evaluated the distribution of both NH2-PVA and COOH-PVA AuNPs in 
different respiratory tract compartments after intranasal administration in BALB/c mice, as well as 
ovalbumin (OVA) uptake, processing and OVA-specific CD4+ T cell proliferation in non-LDLNs and 





Female BALB/c and DO11.10 TCR transgenic (C.Cg-Tg(DO11.10)10DLo/J) mice were bred specific 
pathogen free at the Department of Clinical Research (University of Bern, Switzerland) according to 
the Swiss Federal Veterinary Office guidelines under animal experimentation permission (BE82/12) 



















Intranasal administration of gold nanoparticles (AuNPs) for uptake and trafficking experiments 
NH2-PVA AuNPs and COOH-PVA AuNPs were synthesized and characterized as previously described 
with a slight modification in the molecular weight of PVA (Mowiol 4-88 Mw=31000, Calbiochem, 
EMD Bioscience, Inc. La Jolla, CA, USA) to obtain comparable sizes of both NPs.16,17 Particle synthesis 
and intra-nasal instillation is further described in the online supplementary data section.  
 
CFSE-labeled, OVA-specific CD4+ T cell proliferation in naïve animals  
Lymph nodes from female DO11.10 mice were collected and CD4+ T cells were isolated using a CD4 
negative isolation kit (Dynabeads Untouched Mouse CD4 Cells kit, Invitrogen, Zug, Switzerland). Cells 
were labeled with carboxyfluorescein succinimidyl ester (CFSE; eBioscience, Vienna, Austria) and 107 
stained CD4+ T cells per mouse in 200 μl of PBS were intravenously injected. Two days later, AuNPs 
were administered i.n. as described above, followed by i.n. delivery of 50 μl OVA (Sigma-Aldrich) 
diluted in PBS (1 mg/ml) 15 min later. Three days later, LDLNs or non-LDLNs (inguinal, axial and 
gluteal nodes) were collected and labeled for CD4, the DO11.10 TCR (KJ1-26) and CD69 to determine 
antigen-specific T cell proliferation (CFSE dilution profiles) by flow cytometry. Data was analyzed 
using the proliferation tool of Flow Jo software (Tree Star, Ashland, OR, USA) and proliferation was 
expressed as expansion index (EI).  
 
OVA uptake and processing experiments 
50 μl of AuNPs (200 μg/ml) or of PBS were administered i.n. in anaesthetized mice, followed 15 min 
later by 50 μl of OVA-Alexa Fluor 647 (1 mg/ml; Molecular Probes, Lucerne, Switzerland) or by 50 μl 
of OVA-DQ (1 mg/ml; Molecular Probes) to determine uptake and processing capacity, respectively, 
by APC populations. Animals were euthanized 2h or 24h after exposure and tissue (trachea, lung 
parenchyma, DLNs and BAL) was harvested for preparation of single suspension as described above 




















Unless indicated otherwise, all antibodies were purchased from eBioscience. All stainings were 
performed strictly on ice. Cells were stained with CD11c-APC, CD11c-PerCP-Cy5.5, CD11b-APC-Cy7, 
CD11b-FITC, MHC class II-eF450, CD8α-PE, CD40-FITC (BioLegend), CD86-PE-Cy7 (BioLegend), CD4-
APC-Cy7, DO11.10 TCR (KJ-126)-PE and CD69-PE-Cy7. Apoptosis and necrosis were measured by 
means of Annexin-V-FITC and propidium iodide (PI) staining (BioLegend). Relevant isotype control 
antibodies were employed.  
 
Statistical analysis 
All data are presented as mean ±SEM. Data were analyzed by unpaired Student t-test using GraphPad 
Prism software (La Jolla, CA, USA). Values were considered significantly different with p<0.05 (*), 




We thoroughly characterized both COOH-PVA and NH2-PVA AuNPs by assessing the hydrodynamic 
radius and the polydispersity index (PDI) using dynamic light scattering (DLS), and surface charge 
through zeta potential measurements of NP suspensions in PBS. COOH-PVA AuNPs were negatively-
charged with a zeta potential of -8.2 mV (±1.2 mV) and NH2-PVA AuNPs were positively-charged with 
a zeta potential of 7.2 mV (±2 mV) (Table 1). The hydrodynamic diameter for both AuNPs was 
comprised between 70 nm (PDI 14%) and 90 nm (PDI 23%) (Table 1). Moreover, colloidal stability in 
water, PBS 1x and RPMI 1640 cell culture medium supplemented with 10% fetal calf serum (FCS) was 
determined by optical characterization of UV-Vis spectra and detected no aggregation of AuNPs as 
previously shown.18  The quantification of endotoxin content in AuNPs was done on a regular basis 
and has been described in one of our recent publications. All the used AuNPs suspensions showed 



















Inhaled particle uptake and trafficking by respiratory tract antigen-presenting cells  
To analyze APC-dependent particle uptake and trafficking in different respiratory tract 
compartments, we sampled the BAL (representing the alveolar space), trachea (representing the 
main conducting airways), lung parenchyma (representing the alveolar tissue), and LDLNs in BALB/c 
mice 24h after exposure to either to 50 μl PBS (control), 50 μl NH2-PVA AuNPs or 50 μl COOH-PVA 
AuNPs for 24h. Organs were sampled 24h after exposure to allow sufficient time for particle 
trafficking to LDLNs.13 Control experiments with NH2-PVA and COOH-PVA polymers were also 
included in order to distinguish between effects of the polymer-AuNPs and those of the polymer 
alone. Our gating strategy to identify resident respiratory APC populations includes three different 
populations (online supplementary data, Figure E1): CD11c+ MHC class IIlow macrophages, CD11c+ 
MHC class IIhigh CD103- CD11b+ DCs (“CD11b+ DCs”) and CD11c+ MHC class IIhigh CD103+ CD11b- DCs 
(“CD11b- DCs”).19 In BAL, only CD11b+ DCs were identified. In LDLNs, DC subpopulations were further 
subdivided into migratory CD8α- DCs and resident CD8α+ DCs, yielding four final subsets. This gating 
strategy facilitates analysis of both active cell-dependent transport and passive NP drainage to 
regional LDLNs.13,19 The analyses presented herein only include migratory CD8α- DCs, as no particle-
dependent signals were observed in resident CD8α+ DCs (data not shown), indicating that the 
majority of AuNPs detected in LDLNs are trafficked by cell-mediated transport. Our results showed 
that macrophages from BAL internalized significantly more NH2-PVA AuNPs compared to COOH-PVA 
AuNPs (p=0.0007). This was also observed for polymer alone (p=0.0006) (Figure 1B). There was no 
difference between NH2-PVA AuNPs and NH2-PVA polymer controls, whereas frequencies of 
macrophages positive for COOH-PVA AuNPs were significantly higher than those positive for the 
COOH-PVA polymer alone (p=0.0095). A similar trend was observed in the CD11b+ DC sub-
population. Significant higher uptake of NH2-PVA polymer occurred compared to COOH-PVA polymer 
(p=0.011), but differences in uptake did not reach significance between NH2-PVA AuNPs and COOH-


















in trachea was relatively low (<10%) (Figure 1B) with no significant differences seen in macrophages, 
CD11b- or CD11b+ DCs positive for NH2-PVA compared to COOH-PVA AuNPs and polymers. Within the 
lung parenchyma, macrophages more frequently captured NH2-PVA AuNPs than COOH-PVA AuNPs 
(p=0.013) and NH2-PVA polymer compared to COOH-PVA polymer (p=0.0078) (Figure 1B). CD11b
+ 
and CD11b- DCs also captured AuNPs and their respective polymers, albeit to a much lower extent 
than macrophages (less than 4% of positive cells). Although not significant, there was a trend for 
more frequent capture of NH2-PVA AuNPs compared to COOH-PVA AuNPs both by CD11b
+ DC (p=0.1) 
and CD11b- DC subpopulations (p=0.06). Low frequencies of particle- or polymer-positive migratory 
CD11b+ CD8α- and CD11b- CD8α- DCs were detected in LDLNs, with less than 2% of total gated cells 
(Figure 1B) and no differences seen in trafficking between different particle or polymer types. CD8α+ 
resident DCs were also analyzed but no particle or polymer-dependent signal was detected for this 
cell population (data not shown). The amount of AuNPs taken up by different APC subsets in the 
different lung compartments was also analyzed as measured by mean fluorescence intensity (MFI) 
(Figure E2). No significant MFI differences were measured between the different APC subsets, with 
the only exception of BALF macrophages that internalized significantly more NH2-PVA AuNPs 
compared to COOH-PVA AuNPs (p=0.0347). 
 
OVA-specific CD4+ T cell proliferation after exposure to OVA and AuNPs 
We further examined how NH2-PVA or COOH-PVA AuNPs and respective polymers modulated 
downstream immune responses by measuring antigen-specific CD4+ T cell proliferation in LDLNs. 
Following intranasal exposure to OVA/PBS, OVA/NH2-PVA AuNPs, OVA/NH2-PVA polymers, 
OVA/COOH-PVA AuNPs or OVA/COOH-PVA polymers, proliferation was significantly increased in 
LDLNs compared to non-LDLNs (internal negative-control), in which the EI remained around 1 (Figure 
2C). Significantly increased proliferation was observed in mice exposed to OVA/NH2-PVA AuNPs 
compared to mice receiving OVA/COOH-PVA AuNPs or OVA/PBS. Proliferation in mice exposed to 


















(Figure 2C). These results indicate an intrinsic immuno-modulatory effect of intact NH2-PVA AuNPs 
but not the NH2-PVA polymer alone. 
 
Expression of co-stimulatory molecules CD40 and CD86 after the administration of AuNPs or 
polymers  
To understand if the observed increased proliferation following exposure to NH2-PVA AuNPs was 
dependent on co-stimulatory molecule expression, we assessed CD40 (Figure 3) and CD86 (Figure 4) 
expression on CD11b+ DC, CD11b- DC and macrophage populations in different respiratory tract 
compartments 24h after AuNP or polymer administration. We observed an overall trend for 
increased expression of co-stimulatory molecules on particle- or polymer-containing APCs (“AuNP+” 
in Figures 3 and 4) compared to animals treated with PBS (“PBS” in Figures 3 and 4) or APCs of 
exposed animals not containing particles or polymers (“AuNP-” in Figures 3 and 4). There was no 
detectable difference in CD40 and CD86 expression between mice treated with NH2-PVA AuNPs, 
COOH-PVA AuNPs or the respective polymers. An exception was seen in BAL, where COOH-PVA 
polymers induced significantly increased expression of CD40 and CD86 compared to NH2-PVA 
polymers in macrophages (CD40; p=0.038) and CD11b+ DCs (CD40; p=0.015, and CD86; p=0.049). No 
significant difference was observed between AuNP-treated and polymer-treated groups. 
 
OVA uptake and processing after exposure to OVA and AuNPs 
We next examined whether NH2-PVA AuNPs and COOH-PVA AuNPs induced functional changes in 
APCs by measuring antigen uptake and processing in different respiratory tract compartments. OVA 
coupled to Alexa Fluor-647 and OVA coupled to DQ were used to analyze antigen uptake and antigen 
processing, respectively20. There was an overall trend for increased OVA uptake after 24h exposure 
compared to 2h exposure (Figure 5B), but this reached significance only in BAL macrophages 
(“COOH”, p=0.006) and CD11b+ DCs (“NH2”, p=0.011; “COOH”, p=0.026), in lung parenchyma 


















there was an overall trend for enhanced OVA processing in BAL after 24h compared to the 2h time-
point (Figure 6, upper panels). In the lung parenchyma, significantly increased antigen processing 
occurred in CD11b+ DC populations after 24h for both particle types, while in CD11b- DCs higher 
antigen processing capacity was present early at 2h compared to the 24h late time-point (only 
significant for “COOH”, p=0.034) (Figure 6, middle panels). Finally, in DC populations, OVA processing 
in the LDLNs was significantly higher after 24h compared to after 2h (Figure 6, lower panels). 
 
Discussion 
Colloidal AuNPs are presently used for labeling, drug delivery, heating and sensing in the biomedical 
field.21 For drug delivery, AuNPs offer the advantage that they are straightforward to synthesize, with 
a core size between 1 nm and 150 nm, can be well colloidally stabilized, biocompatible, and may be 
functionalized with molecules via thiol-gold bonds.22 Although numerous in vivo studies on the 
utilization of AuNPs have been performed, e.g. for cell targeting in cancer therapy,23 there is 
insufficient knowledge of how inhaled AuNPs distribute in lung tissues, interact with resident 
immune cells, and whether surface functionalization affects particle-cell interactions. 
 
We aimed to analyze how Au-NP functionalization with two different polymers, NH2-PVA and COOH-
PVA, affected resident APCs and downstream immune responses in the respiratory tract under 
steady-state conditions. Our data indicated that the majority of AuNPs were captured by 
macrophages, although low-grade uptake also occurred in CD11b+ and CD11b- DCs. In BAL and lung 
parenchyma, APC populations more frequently captured NH2-PVA AuNPs compared to COOH-PVA 
AuNPs. Compared to negatively charged COOH-PVA AuNPs or polymers only, we detected enhanced 
OVA-specific CD4+ T cell stimulation in LDLNs following administration of NH2-PVA AuNPs that was 
unrelated to changes in co-stimulatory molecule expression, antigen uptake, or antigen processing in 


















One salient finding in our study was that the majority of AuNPs, independently of their surface 
charge, were taken up by macrophages. Recent studies have emphasized the complex role of 
pulmonary macrophages in inflammatory processes due to their high level of plasticity and their 
ability to polarize into a plethora of different phenotypes depending on signals present in the 
microenvironment,24,25 which may promote either pro- or anti-inflammatory responses.26 One of the 
most important features of respiratory tract macrophages is their distinct phagocytic activity, 
contributing to tissue homeostasis by the clearance of invading pathogens, debris, as well as 
apoptotic cells, and preventing inflammatory responses from occurring in order to maintain vital 
alveolar gas exchange.27,28 Moreover, uptake by macrophages is non-specific and NPs are likely to be 
degraded or inactivated.22 These findings are in line with a study by Geiser and co-workers that 
evaluated the distribution of 21 nm AuNPs following aerosolization in BAL and lung parenchyma of 
wild type mice.29 They observed that 24h after aerosol inhalation, approximately 80% of AuNPs were 
found within macrophages, while the remaining AuNPs were attached to or within epithelial cells. In 
another study utilizing a triple cell co-culture model simulating the alveolar lung epithelium, 15 nm 
AuNPs were found to enter all cell types, i.e. epithelial cells, macrophages and DCs; however a 
quantification of particles per cell type was not performed.30 In the present study, a differential 
uptake between NH2-PVA and COOH-PVA AuNPs was observed, with amine-functionalized, 
positively-charged particles preferentially captured by macrophages as compared to carboxylated 
AuNPs. These results confirm in vitro findings from other groups describing an increased uptake of 
particles with positive charge (e.g. gold, silver, polystyrene, superparamagnetic iron oxide) compared 
to negatively-charged particles.16,31–34 Furthermore, a recent in vivo study with mice exposed to 
hydrogel rod-shaped NPs of different surface charge, showed enhanced uptake by AM, CD11b+ DC 
and CD103+ DC and enhanced trafficking to the LDLNs compared to anionic NPs. The authors of this 
study therefore suggested that cationic NPs may serve as potential immunomodulators in the lung.35 
Despite the fact that we have instilled an NP dosage 10 fold lower than the dosage used in the study 


















evidence of a modulated downstream effector T cell response. The effect of positive particle charge 
may partly be explained by the fact that it favors the adhesion of NPs to the slightly negatively 
charged cell membrane, although previous studies also showed that the overall charge of both 
negatively and positively charged NPs in complete medium is similar34. Furthermore, the number of 
dyes per particle was comparable between the two types of NPs (table 1), therefore differences in 
ATTO590 fluorescent signal in FACS was due to the number of NPs taken up cells rather than due to a 
difference in the number of dyes on the particles.  
We detected relatively lower frequencies of particle-positive CD11b+ and CD11b- DC subpopulations 
compared to macrophages. Specifically targeting DCs to increase particle uptake will be the great 
challenge in the development of novel carriers for vaccines in the respiratory tract and may be 
achieved by coupling ligands (e.g. antibodies) such as anti-DEC205 or anti-DC-SIGN, on the NP surface 
for binding to DC surface receptors.36,37 Similar uptake patterns have already been shown with micro- 
and nano-sized polystyrene particles intra-nasally instilled in mice.13,38,39 However, a striking 
difference in uptake frequency between macrophages and DCs may be explained by the quantity and 
the location of the cells involved. In particular, located at the luminal side of the alveoli, 
macrophages represent the first line of defence against deposited pathogens, while DCs, located 
below the epithelial cells, are present in lower numbers13,40 and are not directly exposed to but take 
up deposited particles by extending their dendrites between the epithelial cells into the alveolar 
lumen as shown by Thornton and co-workers.41 In our study, the amount of AuNP internalized as 
measured by MFI analysis, did not differ between DC subsets and AM, indicating similar endocytic 
activity in lung APC populations analysed. 
Our data indicated that there was no difference in particle uptake between CD11b+ and CD11b- DC 
subpopulations for both types of AuNPs. A previous in vivo study from our group showed that 
negatively-charged polystyrene NPs of identical diameter (100nm) were captured by both CD11b+ 
and CD11b- DC subpopulations to the same extent.13 Notably, migratory CD11b- DCs containing 20 


















DCs, which can be explained by the fact that since CD103 belongs to the integrin family and binds to 
E-cadherin expressed by epithelial cells, CD11b- DCs are known to be located between epithelial cells 
and to extend their dendrites between the epithelial layer directly into the airway lumen to sample 
inhaled antigen deposited in the respiratory tract, allowing to efficiently sample inhaled antigen.42–44 
On the other hand, CD11b+ DCs are expected to be located in the submucosa of the conducting 
airways and parenchyma without crossing the airway epithelial barrier. Hence, they only sample 
antigen that has crossed the basal membrane. Moreover, although no charge-dependent particle 
uptake frequency was seen among different subpopulations of pulmonary DCs, a trend (p=0.06) for 
higher uptake of NH2-PVA AuNPs was found in CD11b
- DC from the lung parenchyma when compared 
to uptake of COOH-PVA AuNPs in this subpopulation. This finding is in line with the results of a recent 
study, where similar AuNPs were tested by exposing human monocyte-derived DCs in vitro.18 
We detected no charge-dependent differences in frequencies of particle-positive CD11b+ and CD11b- 
DCs in LDLNs. Moreover, we did not observe particle-positive resident CD11b+ CD8α+ or CD11b- 
CD8α+ DCs after 24h (data not shown), indicating that passive drainage of both NH2-PVA and COOH-
PVA AuNPs to regional lymph nodes did not take place to any measurable extent. These results are in 
line with a study by Wikstrom and colleagues, which shows that the majority of inhaled antigens 
detected in the LDLNs is associated with CD8α- DCs.45 Also, similar results were found in the study 
already discussed above, where polystyrene particles of a broad size range from 1000 nm down to 20 
nm were mainly found inside CD8α- DCs.13 Detection of both types of AuNPs in LDLNs was low with 
less than 2% of DCs being particle-positive. A possible reason for low detection of AuNPs inside DCs 
of LDLNs may be due to limited sensitivity of the flow cytometry equipment to detect weak signals of 
ATTO590 or low total amounts of intra-cellular AuNPs. Quantification of NPs with remarkable 
sensitivity may be achieved by inductively coupled plasma-optical emission spectroscopy (ICP-OES), a 
method that can quantify intracellular NPs down to a few picograms, and which was used to quantify 


















this technique for in vivo studies would have required extensive cell-sorting which is beyond the 
scope of this study. 
Monitoring T cell activation after AuNP treatment, we made two salient observations: First, a 
significantly increased proliferation of antigen-specific CD4+ T cells occurred in animals exposed to 
co-administered OVA/NH2-PVA AuNPs as compared to mice that received OVA/PBS or OVA/COOH-
PVA AuNPs. Second, NH2-PVA functionalised AuNPs, but not the NH2-PVA polymer alone induced an 
enhanced T cell proliferation. From these two findings three important conclusions may be drawn: 
(1) DC-dependent trafficking of positively-charged NH2-PVA AuNPs and antigen to LDLNs was 
sufficient to induce CD4+ T cell stimulation, (2) NP surface charge determines downstream T cell 
activation, and (3) the "intact" NP core-polymer hybrid is essential to trigger a downstream immune 
responses. Our second conclusion harmonizes well with the current literature where, for example, a 
recent study by Choi and co-workers demonstrated the importance of NP surface charge affecting 
individual trafficking patterns following instillation into the lungs of rats.46 Altered particle trafficking 
to the LDLNs due to particle surface charge may therefore strongly affect downstream immune 
responses. Supporting our third conclusion, another recent study investigating pro-inflammatory 
effects of Iron (Fe)- and Au-NP embedded in a poly(methacrylic acid) (PMA) and particle shells alone, 
also demonstrated altered pro-inflammatory response when coated NPs were compared to shells 
alone or when different cores (with the same PMA coating) were compared together.47 To our 
knowledge the current study is the first description in the field demonstrating that surface charge of 
NPs alters in vivo CD4+ T cell proliferation and that this effect is not restricted to the polymer coating, 
but requires "intact" NPs with a core-bound polymer shell.  
To explain the altered T cell activation with NH2-PVA modified AuNPs we investigated the effect of 
AuNPs on activation and function of respiratory tract DCs. We measured the expression of the co-
stimulatory surface molecules CD40 and CD86 as markers for DC activation following uptake of 
AuNPs. The baseline frequency of expression of both CD40 and CD86 was generally increased in both 


















where COOH-PVA AuNPs and polymers induced a higher expression of CD40 and CD86 compared to 
their NH2 equivalents. A possible explanation for the lower frequencies of activated DCs containing 
NH2-PVA AuNPs in the BAL may be an increased migration of activated DCs from the alveolar space to 
LDLNs, where these cells trigger an increased CD4+ T stimulation. In line with the current study, our 
recent investigation analyzing size-dependent trafficking of different sized polystyrene nanoparticles 
in the respiratory tract of BALB/c mice also revealed the presence of activated macrophages and DCs 
(CD40±, CD86±) following uptake, independent of particle size.13 Also, we observed that the potential 
of DCs to take up and process OVA antigens was also not altered by the exposure to both types of 
AuNPs, therefore increased CD4+ T cell proliferation cannot be explained by an alteration of DC 
activation. Furthermore, we measured levels of early apoptosis and necrosis by means of Annexin-V 
and PI staining in DC and AM populations following exposure to PBS and both types of AuNPs or 
polymers. Our results showed no significantly increased apoptosis or necrosis any treatment group 
compared to PBS controls (Figure E3), indicating that the observed effects of NH2-PVA AuNPs are not 
explained toxicity-related inflammatory responses in the different lung compartments. Other reasons 
for increased proliferation could be explored, such as altered T cell cytokine secretion profiles48 or 
increased adsorption of negatively-charged OVA to positively-charged surface by electrostatic 
attractive interactions.49 Moreover, paralleling AuNP uptake, both CD11b+ and CD11b- DC 
populations in lung parenchyma take up OVA and traffic to LDNLs to the same extent. These results 
are consistent with a study by Wikstrom and al. that analyzed OVA uptake in main conducting 
airways and lung parenchyma, where little difference in OVA uptake by CD11b+ and CD11b- DCs was 
observed.42 OVA processing however, showed a different picture: while processing by CD11b+ DC 
populations in lung parenchyma increased over time, CD11b- DCs showed a higher processing 
capacity after 2h, which then decreases after 24h.42 Lower amounts of OVA+ CD11b- DCs in the lung 
parenchyma after 24h may be explained by increased trafficking of these cells towards to LDLNs 
antigen is taken up and processed. In line with these findings, a study by Belz et al. found as well that 


















In conclusion, this study provides to our knowledge the first evidence that surface charge determines 
uptake of AuNPs by APC subpopulations in different respiratory tract compartments and is able to 
modulate downstream CD4+ T cell proliferation in draining lymph nodes. Moreover, the charge-
dependent effect was not mediated by the polymer alone, but required an "intact" Au core-bound 
polymer. These findings have important implications for the future development of innovative NP-
based carriers for pulmonary drug delivery and emphasize the importance of painstakingly assessing 
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Hydrodynamic diameter [nm] 
(Polydispersity) 
Zeta Potential [mV] (SD) 
Number of dye 
molecules per particle 
COOH-PVA 70 (14 %) -8.2 (1.2) 717 ± 199 
NH2-PVA 90 (23 %) 7.2 (2.0) 568 ± 144 
 
Table 1. Hydrodynamic diameter, zeta potential and number of dye molecules per particle of 
ATTO590-conjugated carboxylic-PVA-functionalized (COOH-PVA) and amine-PVA-functionalized (NH2-



















Figure 1. Quantification of AuNP uptake by APC Populations using flow cytometry 
AuNP or polymer uptake was measured 24h after exposure (A). Gating strategy is described in the 
online supplementary data (Figure E1). Within each APC population cells positive for particles and 
polymers were determined with PBS-exposed animals serving as a control. Results show uptake 
frequencies of NH2-PVA AuNPs (white bars, left), NH2-PVA polymers (white bars, right), COOH-PVA 
AuNPs (black bars, left) and COOH-PVA polymers (black bars, right) by APC populations (B). Results 
are expressed as Δ positive cells = measured frequency in particle-exposed animals minus measured 
frequency in PBS-exposed animals. Y-axes have been scaled differently to illustrate differences 
between groups. Bars show mean ±SEM; *p<0.05, **p<0.005, ***p<0.001 (without bar indication: 
between NH2 and COOH); n=6 independent experiments. 
 
Figure 2. Antigen-specific CD4+ T cell proliferation in lung draining lymph nodes (LDLNs) and non-
draining lymph nodes (non-DLNs) following intranasal exposure to OVA and AuNPs, polymers or 
PBS 
(A) Seventy two hours after administration, CD4+ DO11.10+ T cell proliferation in non-DLNs (internal 
negative control) and LDLNs was assessed by flow cytometry. (B) Gating strategy included a FSC and 
SSC gating followed by a CD4+ DO11.10+ gating. Histograms of CFSE profiles in non-DLNs (left) and 
LDLNs (right) were analyzed in order to obtain the expansion index (EI). (C) EI values for CD4+ 
DO11.10+ T cells in non-DLNs (left) and LDLNs (right) after exposure to PBS (white), NH2-PVA AuNPs 
(grey), NH2-PVA polymers (grey), COOH-PVA AuNPs (black) or COOH-PVA polymers (black). Bars show 
mean ±SEM; *p<0.05, ***p<0.001; n=5 independent experiments. 
 



















Expression of CD40 was determined 24h after administration in particle-positive (“AuNP+”) and 
particle-negative (“AuNP-“) cell populations within the same animal and compared to PBS-exposed 
animals (“PBS”). Results are expressed as Δ frequency = measured sample frequency minus 
measured isotype control frequency. White bars: PBS; light grey bars: NH2-PVA AuNPs; striped light 
grey bars: NH2-PVA polymers; dark grey bars: COOH-PVA AuNPs; striped dark grey bars: COOH-PVA 
polymers. Bars show mean ±SEM; *p<0.05, **p<0.005, ***p<0.001; n=5 independent experiments. 
 
Figure 4. CD86 expression in APC populations following particle exposure measured by flow 
cytometry 
Expression of CD86 was determined 24h after administration in particle-positive (“AuNP+”) and 
particle-negative (“AuNP-“) cell populations within the same animal and was compared to PBS-
exposed animals (“PBS”). Results are expressed as Δ frequency = measured sample frequency minus 
measured isotype control frequency. White bars: PBS; light grey bars: NH2-PVA AuNPs; striped light 
grey bars: NH2-PVA polymers; dark grey bars: COOH-PVA AuNPs; striped dark grey bars: COOH-PVA 
polymers. Bars show mean ±SEM; *p<0.05, **p<0.005 (without bar indication: between AuNP- and 
AuNP+); n=5 independent experiments. 
 
Figure 5. Antigen uptake by APC populations following exposure to PBS or AuNPs  
(A) Mice were administrated intra-nasally PBS only (“ctrl”), PBS + OVA-Alexa Fluor647 (“PBS”), NH2-
PVA AuNPs + OVA-Alexa Fluor647 (“NH2”) or COOH-PVA AuNPs + OVA-Alexa Fluor647 (“COOH”), 
prior to measuring OVA uptake flow cytometry. (B) Results show uptake after 2 hours (white) and 24 
hours (black) by APC populations in BAL, lung parenchyma and LDLNs. Results are expressed as mean 
fluorescence intensity. Y-axes have been scaled differently to illustrate differences between groups. 
Bars show mean ±SEM; *p<0.05, **p<0.005; n=5 independent experiments. 
 


















Mice were administrated intra-nasally PBS only (“ctrl”), PBS + DQ-OVA (“PBS”), NH2-PVA AuNPs + DQ-
OVA (“NH2”) or COOH-PVA AuNPs + DQ-OVA (“COOH”). Results show processing after 2 hours (white) 
and 24 hours (black) by APC populations in BAL, lung parenchyma and LDLNs. Results are expressed 
as mean fluorescence intensity. Y-axes have been scaled differently to illustrate differences between 
















































































































































CD4+ T cell proliferation in lung draining lymph nodes was measured after intra nasal instillation of 
positively (NH2) charged and negatively charged (COOH) gold nanoparticles or polymer shells alone 
followed by ovalbumin in a mouse model of ovalbumin induced experimental allergic airways disease 
(upper panel). Positively charged gold nanoparticles induced enhanced ovalbumin specific T cell 
proliferation compared to controls (non-exposed), negatively charged gold nanoparticles or positively 
charged polymer alone (lower panel). This and other findings of the present study highlight the 
importance of surface charge of a biomedical nanoparticle in modulating a specific adaptive immune 
response. 
 
 
 
